Ayesha A. Shafi

This study identifies CRY1 as a stage-specific regulator of DNA damage repair in prostate cancer, showing it promotes NHEJ/BER in hormone-sensitive disease and HR in castration-resistant disease.

This study uses proteogenomics to identify ancestry-specific and shared molecular drivers in prostate cancer, revealing distinct biological programs and improving risk prediction.

This study examines how PARP inhibitors affect transcriptional responses in prostate cancer patients of different racial backgrounds, finding race-based differences in PARP1 expression and distinct transcriptional programs for each inhibitor.

This paper identifies the EZH2-TTP-mTORC1 axis as a driver of phenotypic plasticity and therapeutic vulnerability in prostate cancer, showing that combined inhibition of EZH2 and PI3K/mTORC1 improves anti-tumor activity.

This study identifies CBP/p300 as critical for DNA repair in prostate cancer and shows that targeting it enhances therapeutic response.

The paper compares the chromatin binding and transcriptional activities of AR and AR-V7 in prostate cancer cells, finding distinct cistromes and transcriptomes.